bpc-157 synthetic stable gastric pentadecapeptide & The Gut-Brain Axis: A Practitioner's Definitive Review of the Evidence BPC-157 vs. TB-500: What Patients

Regarding the patients without a history of gastrectomy, topical antifungal therapy (nystatin suspension 4 mL of 100,000 units/mL, 3 times/day, topical) was administered to 6 patients, CMC-based artificial saliva and clonazepam (0.5 - 1.0 mg/day, topical and/or p.o.) to 4 patients, and CMC-based artificial saliva only to 1 patient

While both are frequently referenced in similar research areas, they differ in their mechanisms and primary areas of investigation

BPC-157 is a research compound and has not been approved by Health Canada for human consumption or therapeutic use

So, while we are eradicating and healing from SIBO, what can we do about managing the constipation that comes with it